Literature DB >> 21881483

Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34.

Amy E Rose1, Paul J Christos, Dan Lackaye, Richard L Shapiro, Russell Berman, Madhu Mazumdar, Hideko Kamino, Iman Osman, Farbod Darvishian.   

Abstract

Immunohistochemistry (IHC) using endothelial markers may facilitate the detection of lymphovascular invasion (LVI) in primary melanoma; however, the clinical implications of enhanced detection are unknown. We evaluated whether the use of lymphatic endothelial marker D2-40 and panvascular marker CD34 increases LVI positivity relative to routine histology alone and then evaluated the prognostic relevance of LVI detected using these markers in terms of disease-free (DFS) and overall survival (OS). A total of 246 primary melanomas were assessed for LVI using D2-40, CD34, and routine histology. Associations between LVI positivity and clinicopathologic variables, DFS, and OS were compared using univariate and multivariate analyses. The use of endothelial markers increased the rate of LVI positivity (18% using D2-40 and/or CD34 vs. 3% by routine histology, P<0.0001). On univariate analysis, IHC-detected LVI was significantly associated with more adverse clinicopathologic variables (thickness, ulceration, mitoses, and nodular subtype) compared with LVI detected by routine histology (thickness and ulceration only). In a multivariate model controlling for stage, LVI detected using IHC markers remained a significant marker of both reduced DFS [hazard ratio (HR), 2.01; 95% confidence interval (CI): 1.27-3.18; P=0.003] and OS (HR, 2.08; 95% CI: 1.25-3.46; P=0.005). Results show that D2-40 and CD34 increase the detection of LVI in primary melanoma and that cases missed by routine histology have prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881483      PMCID: PMC3623282          DOI: 10.1097/PAS.0b013e31822573f5

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

1.  A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors.

Authors:  Harriette J Kahn; Alexander Marks
Journal:  Lab Invest       Date:  2002-09       Impact factor: 5.662

2.  First--select the target: better choice of adjuvant treatments for breast cancer patients.

Authors:  A Goldhirsch; A S Coates; R D Gelber; J H Glick; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2006-10-27       Impact factor: 32.976

3.  Vascular involvement in the prognosis of primary cutaneous melanoma.

Authors:  M Kashani-Sabet; R W Sagebiel; C M Ferreira; M Nosrati; J R Miller
Journal:  Arch Dermatol       Date:  2001-09

4.  Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.

Authors:  H E Wiley; E B Gonzalez; W Maki; M T Wu; S T Hwang
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

5.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

6.  Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.

Authors:  Matthew Petitt; Ashley Allison; Tally Shimoni; Tatsuo Uchida; Sharon Raimer; Brent Kelly
Journal:  J Am Acad Dermatol       Date:  2009-11       Impact factor: 11.527

7.  Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Authors:  Firouzeh Niakosari; Harriette J Kahn; David McCready; Danny Ghazarian; Lorne E Rotstein; Alexander Marks; Alexander Kiss; Lynn From
Journal:  Arch Dermatol       Date:  2008-04

8.  Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Authors:  Xiaowei Xu; Phyllis A Gimotty; Dupont Guerry; Giorgos Karakousis; Patricia Van Belle; Haohai Liang; Katharine Montone; Terry Pasha; Michael E Ming; Geza Acs; Michael Feldman; Stephen Barth; Rachel Hammond; Rosalie Elenitsas; Paul J Zhang; David E Elder
Journal:  Hum Pathol       Date:  2008-04-28       Impact factor: 3.466

9.  Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival.

Authors:  Fredrik Petersson; A Hafeez Diwan; Doina Ivan; Jeffrey E Gershenwald; Marcella M Johnson; Robyn Harrell; Victor G Prieto
Journal:  J Cutan Pathol       Date:  2009-02-05       Impact factor: 1.587

10.  Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study.

Authors:  G G Van den Eynden; I Van der Auwera; S J Van Laere; C G Colpaert; P van Dam; L Y Dirix; P B Vermeulen; E A Van Marck
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

View more
  15 in total

1.  Long-Term Outcomes of Endoscopic Versus Surgical Resection of Superficial Submucosal Colorectal Cancer.

Authors:  Ji-Beom Kim; Ho Su Lee; Hyo Jeong Lee; Jihun Kim; Dong-Hoon Yang; Chang Sik Yu; Jin Cheon Kim; Jeong-Sik Byeon
Journal:  Dig Dis Sci       Date:  2015-01-14       Impact factor: 3.199

2.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

3.  Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.

Authors:  Xiaowei Xu; Phyllis A Gimotty; Dupont Guerry; Giorgos Karakousis; David E Elder
Journal:  Methods Mol Biol       Date:  2014

Review 4.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

5.  Lymphatic invasion and angiotropism in primary cutaneous melanoma.

Authors:  Andrea P Moy; Lyn M Duncan; Stefan Kraft
Journal:  Lab Invest       Date:  2016-12-19       Impact factor: 5.662

6.  Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?

Authors:  Patrick Scanlon; Jaiying Tian; Judy Zhong; Ines Silva; Richard Shapiro; Anna Pavlick; Russell Berman; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2014-04-18       Impact factor: 3.466

Review 7.  Emerging Biomarkers in Cutaneous Melanoma.

Authors:  Anna Eisenstein; Estela Chen Gonzalez; Rekha Raghunathan; Xixi Xu; Muzhou Wu; Emily O McLean; Jean McGee; Byungwoo Ryu; Rhoda M Alani
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

8.  Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study.

Authors:  Aaron M Udager; Jonathan B McHugh; Todd M Morgan; Daniel E Spratt; Arul M Chinnaiyan; Rohit Mehra
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019 May/Jun

9.  The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Authors:  Rosalyn Jewell; Faye Elliott; Jonathan Laye; Jérémie Nsengimana; John Davies; Christy Walker; Caroline Conway; Angana Mitra; Mark Harland; Martin G Cook; Andy Boon; Sarah Storr; Sabreena Safuan; Stewart G Martin; Karin Jirström; Håkan Olsson; Christian Ingvar; Martin Lauss; Tim Bishop; Göran Jönsson; Julia Newton-Bishop
Journal:  Pigment Cell Melanoma Res       Date:  2014-10-01       Impact factor: 4.693

10.  Optimizing Detection of Lymphatic Invasion in Primary Cutaneous Melanoma With the Use of D2-40 and a Paired Melanocytic Marker.

Authors:  Richard J Straker; Laura A Taylor; Madalyn G Neuwirth; Andrew J Sinnamon; Adrienne B Shannon; James Abbott; John T Miura; Emily Y Chu; Xiaowei Xu; Giorgos C Karakousis
Journal:  Am J Dermatopathol       Date:  2022-01-01       Impact factor: 1.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.